特雷梅利马布:对晚期或不可切除的肝细胞癌的综述
Nicole L France1, Hannah A Blair2
1Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. demail@springer.com.
Targeted oncology
|January 18, 2024
概括
结合特梅利马布和杜尔瓦马布的STRIDE疗法显著改善了不可切除的肝细胞癌 (HCC) 的整体存活率. 这种免疫检查点抑制剂组合为高级HCC患者提供了一种有价值的新一线治疗选择.
科学领域:
- 免疫治疗是一种免疫疗法.
- 在瘤学瘤学.
- 肝细胞癌研究 肝细胞癌研究
背景情况:
- 特梅利利马布是一种CTLA-4阻断单克隆抗体.
- 杜尔瓦卢马布是一种PD-L1阻断免疫检查点抑制剂.
- STRIDE疗法将这些药物结合起来,用于不可切除的HCC治疗.
研究的目的:
- 评估STRIDE治疗方案在不可切除的HCC的第一线治疗中的疗效和安全性.
- 为了在HIMALAYA试验中比较STRIDE疗法与sorafenib.
主要方法:
- 第三阶段的HIMALAYA试验.
- 组合疗法:特雷梅利木马布 (单剂量) + 杜尔瓦卢马布 (ICI) 与索拉费尼布.
- 评估整体生存率 (OS) 和客观反应率.
主要成果:
- 与索拉费尼布相比,STRIDE显著改善了操作系统.
- 在STRIDE中观察到更高的客观响应率.
- 在4年随访后,持续的OS益处.
- 可管理的安全概况,与索拉芬尼比较少的3/4级不良事件.
结论:
- 在STRIDE疗法中,特梅利利马布是先进或不可切除的HCC的有价值的第一线选择.
- STRIDE扩大了无法切除的HCC患者的治疗选择.
- 该疗法证明了持续的疗效和有利的安全性.
更多相关视频
相关概念视频
01:27Tumor Immunotherapy
527
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
527
02:57Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K